vTv Therapeutics (VTVT)
Market Price (10/7/2026): $0 | Market Cap: $-Sector: Health Care | Industry: Biotechnology
vTv Therapeutics (VTVT)
Market Price (10/7/2026): $0Market Cap: $-Sector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -23% Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 216600% Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. | Weak multi-year price returns3Y Excs Rtn is -25% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -9.3 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -25% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 14% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -46%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -46% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -5.0% Key risksVTVT key risks include [1] the uncertain regulatory approval of its lead type 1 diabetes drug, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -23% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 216600% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. |
| Weak multi-year price returns3Y Excs Rtn is -25% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -9.3 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -25% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 14% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -46%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -46% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -5.0% |
| Key risksVTVT key risks include [1] the uncertain regulatory approval of its lead type 1 diabetes drug, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 10/1/2026
vTv Therapeutics (VTVT) stock has lost about 20% since 6/30/2026 because of the following key factors:
1. Fiscal Q2 2026 Financial Results Missed Analyst Estimates and Showed Increased Net Loss.
vTv Therapeutics reported a net loss of $13.1 million for fiscal Q2 2026, or $1.05 per basic and diluted share, which missed the analyst consensus estimate of -$0.97 per share by $0.08. This represented a substantial increase from the $6.0 million net loss reported in fiscal Q2 2025. Research and Development (R&D) expenses rose to $8.8 million in fiscal Q2 2026, up from $4.1 million in the prior year's comparable period, primarily driven by investments in the Phase 3 CATT1 trial. While the company stated its cash and cash equivalents of $86.6 million as of June 30, 2026, were sufficient to fund operations through the anticipated CATT1 topline data readout, the higher net loss and increased cash burn likely contributed to investor caution.
2. Extended Timeline for Cadisegliatin Phase 3 Trial Data Readout.
Despite expectations for completing enrollment in the Phase 3 CATT1 trial for cadisegliatin in Type 1 Diabetes (T1D) during fiscal Q3 2026, the anticipated topline data readout is not projected until fiscal 2027. This extended waiting period for pivotal clinical trial results, even with ongoing progress in enrollment, can lead to a lack of immediate positive catalysts for the stock. Such a prolonged timeline for critical data in the biotechnology sector can often result in investor impatience and contribute to stock price weakness.
Show more
vTv Therapeutics (VTVT) stock has lost about 20% since 6/30/2026 because of the following key factors:
1. Fiscal Q2 2026 Financial Results Missed Analyst Estimates and Showed Increased Net Loss.
vTv Therapeutics reported a net loss of $13.1 million for fiscal Q2 2026, or $1.05 per basic and diluted share, which missed the analyst consensus estimate of -$0.97 per share by $0.08. This represented a substantial increase from the $6.0 million net loss reported in fiscal Q2 2025. Research and Development (R&D) expenses rose to $8.8 million in fiscal Q2 2026, up from $4.1 million in the prior year's comparable period, primarily driven by investments in the Phase 3 CATT1 trial. While the company stated its cash and cash equivalents of $86.6 million as of June 30, 2026, were sufficient to fund operations through the anticipated CATT1 topline data readout, the higher net loss and increased cash burn likely contributed to investor caution.
2. Extended Timeline for Cadisegliatin Phase 3 Trial Data Readout.
Despite expectations for completing enrollment in the Phase 3 CATT1 trial for cadisegliatin in Type 1 Diabetes (T1D) during fiscal Q3 2026, the anticipated topline data readout is not projected until fiscal 2027. This extended waiting period for pivotal clinical trial results, even with ongoing progress in enrollment, can lead to a lack of immediate positive catalysts for the stock. Such a prolonged timeline for critical data in the biotechnology sector can often result in investor impatience and contribute to stock price weakness.
Show more
Updated on 10/1/2026
vTv Therapeutics (VTVT) stock has lost about 20% since 6/30/2026 because of the following key factors:
1. Fiscal Q2 2026 Financial Results Missed Analyst Estimates and Showed Increased Net Loss.
vTv Therapeutics reported a net loss of $13.1 million for fiscal Q2 2026, or $1.05 per basic and diluted share, which missed the analyst consensus estimate of -$0.97 per share by $0.08. This represented a substantial increase from the $6.0 million net loss reported in fiscal Q2 2025. Research and Development (R&D) expenses rose to $8.8 million in fiscal Q2 2026, up from $4.1 million in the prior year's comparable period, primarily driven by investments in the Phase 3 CATT1 trial. While the company stated its cash and cash equivalents of $86.6 million as of June 30, 2026, were sufficient to fund operations through the anticipated CATT1 topline data readout, the higher net loss and increased cash burn likely contributed to investor caution.
2. Extended Timeline for Cadisegliatin Phase 3 Trial Data Readout.
Despite expectations for completing enrollment in the Phase 3 CATT1 trial for cadisegliatin in Type 1 Diabetes (T1D) during fiscal Q3 2026, the anticipated topline data readout is not projected until fiscal 2027. This extended waiting period for pivotal clinical trial results, even with ongoing progress in enrollment, can lead to a lack of immediate positive catalysts for the stock. Such a prolonged timeline for critical data in the biotechnology sector can often result in investor impatience and contribute to stock price weakness.
3. Persistent Investor Concerns Regarding Future Funding and Market Potential.
Ongoing concerns highlighted by analysts, particularly the "bear" perspectives, likely weighed on vTv Therapeutics' stock performance. These concerns include a "high cash burn rate and limited revenue streams, potentially putting them at risk for future funding needs". Furthermore, analysts noted "competition from emerging curative treatments for T1D" and "uncertainty around the long-term efficacy and safety" of cadisegliatin, suggesting limitations to the drug's potential market and contributing to short-term stock volatility. The absence of overwhelmingly positive company-specific news during fiscal Q3 2026 to counteract these existing anxieties likely exacerbated negative sentiment.
Show less
vTv Therapeutics (VTVT) stock has lost about 20% since 6/30/2026 because of the following key factors:
1. Fiscal Q2 2026 Financial Results Missed Analyst Estimates and Showed Increased Net Loss.
vTv Therapeutics reported a net loss of $13.1 million for fiscal Q2 2026, or $1.05 per basic and diluted share, which missed the analyst consensus estimate of -$0.97 per share by $0.08. This represented a substantial increase from the $6.0 million net loss reported in fiscal Q2 2025. Research and Development (R&D) expenses rose to $8.8 million in fiscal Q2 2026, up from $4.1 million in the prior year's comparable period, primarily driven by investments in the Phase 3 CATT1 trial. While the company stated its cash and cash equivalents of $86.6 million as of June 30, 2026, were sufficient to fund operations through the anticipated CATT1 topline data readout, the higher net loss and increased cash burn likely contributed to investor caution.
2. Extended Timeline for Cadisegliatin Phase 3 Trial Data Readout.
Despite expectations for completing enrollment in the Phase 3 CATT1 trial for cadisegliatin in Type 1 Diabetes (T1D) during fiscal Q3 2026, the anticipated topline data readout is not projected until fiscal 2027. This extended waiting period for pivotal clinical trial results, even with ongoing progress in enrollment, can lead to a lack of immediate positive catalysts for the stock. Such a prolonged timeline for critical data in the biotechnology sector can often result in investor impatience and contribute to stock price weakness.
3. Persistent Investor Concerns Regarding Future Funding and Market Potential.
Ongoing concerns highlighted by analysts, particularly the "bear" perspectives, likely weighed on vTv Therapeutics' stock performance. These concerns include a "high cash burn rate and limited revenue streams, potentially putting them at risk for future funding needs". Furthermore, analysts noted "competition from emerging curative treatments for T1D" and "uncertainty around the long-term efficacy and safety" of cadisegliatin, suggesting limitations to the drug's potential market and contributing to short-term stock volatility. The absence of overwhelmingly positive company-specific news during fiscal Q3 2026 to counteract these existing anxieties likely exacerbated negative sentiment.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The -20.2% change in VTVT stock from 6/30/2026 to 10/6/2026 was primarily driven by a -20.2% change in the company's P/S Multiple.| (LTM values as of) | 6302026 | 10062026 | Change |
|---|---|---|---|
| Stock Price ($) | 37.65 | 30.03 | -20.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 37 | 37 | 0.0% |
| P/S Multiple | 12.7 | 10.1 | -20.2% |
| Shares Outstanding (Mil) | 12 | 12 | 0.0% |
| Cumulative Contribution | -20.2% |
Market Drivers
6/30/2026 to 10/6/2026| Return | Correlation | |
|---|---|---|
| VTVT | -20.2% | |
| Market (SPY) | 4.3% | 4.9% |
| Sector (XLV) | 5.3% | 9.5% |
Fundamental Drivers
The -24.3% change in VTVT stock from 3/31/2026 to 10/6/2026 was primarily driven by a null change in the company's P/S Multiple.| (LTM values as of) | 3312026 | 10062026 | Change |
|---|---|---|---|
| Stock Price ($) | 39.66 | 30.03 | -24.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 37 | 9.2233720368547763E17% |
| P/S Multiple | ∞ | 10.1 | |
| Shares Outstanding (Mil) | 12 | 12 | 0.3% |
| Cumulative Contribution | 0.0% |
Market Drivers
3/31/2026 to 10/6/2026| Return | Correlation | |
|---|---|---|
| VTVT | -24.3% | |
| Market (SPY) | 20.1% | 19.6% |
| Sector (XLV) | 14.5% | 13.8% |
Fundamental Drivers
The 28.6% change in VTVT stock from 9/30/2025 to 10/6/2026 was primarily driven by a 216600.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 9302025 | 10062026 | Change |
|---|---|---|---|
| Stock Price ($) | 23.35 | 30.03 | 28.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 37 | 216600.0% |
| P/S Multiple | 9,047.5 | 10.1 | -99.9% |
| Shares Outstanding (Mil) | 7 | 12 | -46.9% |
| Cumulative Contribution | 28.6% |
Market Drivers
9/30/2025 to 10/6/2026| Return | Correlation | |
|---|---|---|
| VTVT | 28.6% | |
| Market (SPY) | 17.9% | 18.9% |
| Sector (XLV) | 21.6% | 9.9% |
Fundamental Drivers
The 57.1% change in VTVT stock from 9/30/2023 to 10/6/2026 was primarily driven by a 409222.2% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 9302023 | 10062026 | Change |
|---|---|---|---|
| Stock Price ($) | 19.12 | 30.03 | 57.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 37 | 409222.2% |
| P/S Multiple | 4,429.4 | 10.1 | -99.8% |
| Shares Outstanding (Mil) | 2 | 12 | -83.2% |
| Cumulative Contribution | 57.1% |
Market Drivers
9/30/2023 to 10/6/2026| Return | Correlation | |
|---|---|---|
| VTVT | 57.1% | |
| Market (SPY) | 88.5% | 13.3% |
| Sector (XLV) | 35.9% | 7.1% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| VTVT Return | -47% | -33% | -57% | 20% | 190% | -24% | -59% |
| Peers Return | -15% | -20% | -11% | 0% | -35% | -50% | -80% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 14% | 107% |
Monthly Win Rates [3] | |||||||
| VTVT Win Rate | 25% | 33% | 17% | 50% | 58% | 40% | |
| Peers Win Rate | 46% | 31% | 44% | 47% | 47% | 22% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| VTVT Max Drawdown | -72% | -61% | -79% | -55% | -40% | -32% | |
| Peers Max Drawdown | -35% | -40% | -49% | -45% | -59% | -50% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: VRTX, CMND, CNSY, CNXU, CSBR.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 10/6/2026 (YTD)
How Low Can It Go
| Event | VTVT | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -30.3% | -18.8% |
| % Gain to Breakeven | 43.4% | 23.1% |
| Time to Breakeven | 6 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -38.7% | -7.8% |
| % Gain to Breakeven | 63.3% | 8.5% |
| Time to Breakeven | 186 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -65.8% | -9.5% |
| % Gain to Breakeven | 192.7% | 10.5% |
| Time to Breakeven | 114 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -17.9% | -6.7% |
| % Gain to Breakeven | 21.7% | 7.1% |
| Time to Breakeven | 890 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -60.7% | -24.5% |
| % Gain to Breakeven | 154.4% | 32.4% |
| Time to Breakeven | 77 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -41.2% | -33.7% |
| % Gain to Breakeven | 69.9% | 50.9% |
| Time to Breakeven | 56 days | 140 days |
In The Past
vTv Therapeutics's stock fell -30.3% during the 2025 US Tariff Shock. Such a loss loss requires a 43.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | VTVT | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -30.3% | -18.8% |
| % Gain to Breakeven | 43.4% | 23.1% |
| Time to Breakeven | 6 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -38.7% | -7.8% |
| % Gain to Breakeven | 63.3% | 8.5% |
| Time to Breakeven | 186 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -65.8% | -9.5% |
| % Gain to Breakeven | 192.7% | 10.5% |
| Time to Breakeven | 114 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -60.7% | -24.5% |
| % Gain to Breakeven | 154.4% | 32.4% |
| Time to Breakeven | 77 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -41.2% | -33.7% |
| % Gain to Breakeven | 69.9% | 50.9% |
| Time to Breakeven | 56 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -69.7% | -19.2% |
| % Gain to Breakeven | 230.1% | 23.8% |
| Time to Breakeven | 424 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -35.1% | -3.7% |
| % Gain to Breakeven | 54.2% | 3.9% |
| Time to Breakeven | 116 days | 6 days |
In The Past
vTv Therapeutics's stock fell -30.3% during the 2025 US Tariff Shock. Such a loss loss requires a 43.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About vTv Therapeutics (VTVT)
vTv Therapeutics Inc. (VTVT) is a clinical-stage biopharmaceutical company focused on discovering and developing novel, orally administered small molecule treatments. The company's core mission is to address significant unmet medical needs across various therapeutic areas, with a strong emphasis on metabolic diseases, particularly diabetes, as well as inflammatory conditions.
The company's pipeline features several key drug candidates. Its most advanced program, TTP399, is an oral, liver-selective glucokinase activator currently in development for the treatment of Type 1 diabetes. Another lead product candidate is HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor designed to treat inflammatory diseases and psoriasis. VTVT also develops other programs targeting conditions such as cystic fibrosis related diabetes, chronic diseases associated with oxidative stress, inflammatory lung diseases (including severe COVID-19), and certain cancers, often leveraging strategic partnerships for development and commercialization.
AI Analysis | Feedback
- Novo Nordisk, but for a pipeline of oral diabetes drugs.
- Vertex Pharmaceuticals, but developing oral drugs for diabetes and inflammatory conditions.
AI Analysis | Feedback
```html
- TTP399: An orally administered, liver-selective glucokinase activator for treating type 1 diabetes.
- HPP737: An orally administered non-CNS penetrant PDE4 inhibitor addressing inflammatory diseases and psoriasis.
- TTP273: An oral small molecule GLP-1 receptor agonist designed to treat postprandial glucose excursion in cystic fibrosis related diabetes.
- HPP3033: A non-electrophilic therapeutic approach to activating the Nrf2 pathway for chronic diseases associated with oxidative stress.
- Azeliragon: A RAGE antagonist being developed for inflammatory lung diseases (including severe COVID-19) and certain cancers.
- HPP971: An Nrf2 activator developed for renal diseases, through pharmaceutical partnerships.
- HPP593: A compound part of a peroxisome proliferation activated receptor delta agonist program.
AI Analysis | Feedback
vTv Therapeutics Inc. (VTVT) is a clinical-stage biopharmaceutical company. As such, it does not sell finished pharmaceutical products directly to individuals. Instead, its primary business model involves research and development, with revenue generated through partnerships, licensing agreements, and collaborations with other pharmaceutical companies and organizations.
Based on the provided company description, vTv Therapeutics' major customers or partners, through licensing and research agreements, include the following companies:
- Reneo Pharmaceuticals, Inc. (RPHM)
- Novo Nordisk A/S (NVO)
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- Newsoara Biopharma Co., Ltd.
AI Analysis | Feedback
null
AI Analysis | Feedback
Paul Sekhri, Chairman of the Board, President and CEO
Paul Sekhri has over 35 years of experience in the Life Science Industry, with senior management experience in large corporate pharmaceutical and biotechnology companies, as well as private equity and venture capital. He is currently Chairman, President, and Chief Executive Officer of vTv Therapeutics, Inc. Prior to joining vTv, he served as President and CEO of eGenesis, Inc. from 2019 to 2022, and President and CEO of Lycera Corp. from 2015 to 2018. Mr. Sekhri was the Founder, President, and Chief Executive Officer of Cerimon Pharmaceuticals, Inc. from 2004 to 2009. He also spent five years as Operating Partner and Head of the Biotechnology Operating Group at TPG Biotech, the life sciences venture capital arm of TPG Capital. His previous roles include Senior Vice President, Integrated Care for Sanofi, and Group Executive Vice President, Global Business Development and Chief Strategy Officer for Teva Pharmaceutical Industries, Ltd.
Dr. Michael Tung, Chief Financial Officer
Dr. Michael Tung brings over 20 years of financial management, investment experience, and strategic leadership for both private and public companies in the life sciences industry. He was appointed Executive Vice President and Chief Financial Officer of vTv Therapeutics Inc. in May 2025. Prior to joining vTv, Dr. Tung was the chief financial officer of AdvanCell Pty Limited from August 2023 to January 2025. From April 2020 until July 2023, he held the position of vice president-corporate strategy/investor relations with FibroGen Inc. He also served as senior vice president-corporate strategy/investor relations at Aclaris Therapeutics, Inc. from July 2016 to September 2019. Before Aclaris, Dr. Tung managed healthcare-dedicated funds as a portfolio manager at several firms. He is a licensed physician.
Rich Nelson, Executive Vice President, Corporate Development
Rich Nelson joined the vTv Board of Directors in 2020 and currently serves as Executive Vice President Corporate & Business Development of Vericast, and Executive Vice President Corporate Development for MacAndrews & Forbes. He has more than 25 years of business and legal experience in mergers & acquisitions and corporate development. Mr. Nelson is also an active venture investor and advisor to various stage private companies and their Boards.
Carmen Valcarce, Executive Vice President, Chief Scientific Officer
Carmen Valcarce has over 30 years of pharmaceutical research and development experience, primarily focused on the metabolic space. She was instrumental in advancing the company's Glucokinase Activator program (TTP399) from an idea to clinical development. Carmen was part of the vTv IPO team, having joined the company through its previous partnership with Novo Nordisk. She has managed more than 12 Investigational New Drug (IND) applications and conducted numerous positive clinical studies in diabetes.
Paul Sekhri has over 35 years of experience in the Life Science Industry, with senior management experience in large corporate pharmaceutical and biotechnology companies, as well as private equity and venture capital. He is currently Chairman, President, and Chief Executive Officer of vTv Therapeutics, Inc. Prior to joining vTv, he served as President and CEO of eGenesis, Inc. from 2019 to 2022, and President and CEO of Lycera Corp. from 2015 to 2018. Mr. Sekhri was the Founder, President, and Chief Executive Officer of Cerimon Pharmaceuticals, Inc. from 2004 to 2009. He also spent five years as Operating Partner and Head of the Biotechnology Operating Group at TPG Biotech, the life sciences venture capital arm of TPG Capital. His previous roles include Senior Vice President, Integrated Care for Sanofi, and Group Executive Vice President, Global Business Development and Chief Strategy Officer for Teva Pharmaceutical Industries, Ltd.
Dr. Michael Tung, Chief Financial Officer
Dr. Michael Tung brings over 20 years of financial management, investment experience, and strategic leadership for both private and public companies in the life sciences industry. He was appointed Executive Vice President and Chief Financial Officer of vTv Therapeutics Inc. in May 2025. Prior to joining vTv, Dr. Tung was the chief financial officer of AdvanCell Pty Limited from August 2023 to January 2025. From April 2020 until July 2023, he held the position of vice president-corporate strategy/investor relations with FibroGen Inc. He also served as senior vice president-corporate strategy/investor relations at Aclaris Therapeutics, Inc. from July 2016 to September 2019. Before Aclaris, Dr. Tung managed healthcare-dedicated funds as a portfolio manager at several firms. He is a licensed physician.
Rich Nelson, Executive Vice President, Corporate Development
Rich Nelson joined the vTv Board of Directors in 2020 and currently serves as Executive Vice President Corporate & Business Development of Vericast, and Executive Vice President Corporate Development for MacAndrews & Forbes. He has more than 25 years of business and legal experience in mergers & acquisitions and corporate development. Mr. Nelson is also an active venture investor and advisor to various stage private companies and their Boards.
Carmen Valcarce, Executive Vice President, Chief Scientific Officer
Carmen Valcarce has over 30 years of pharmaceutical research and development experience, primarily focused on the metabolic space. She was instrumental in advancing the company's Glucokinase Activator program (TTP399) from an idea to clinical development. Carmen was part of the vTv IPO team, having joined the company through its previous partnership with Novo Nordisk. She has managed more than 12 Investigational New Drug (IND) applications and conducted numerous positive clinical studies in diabetes.
AI Analysis | Feedback
Key Risks to vTv Therapeutics (VTVT)
- Clinical Trial Failure and Inability to Obtain Regulatory Approval: As a clinical-stage biopharmaceutical company, vTv Therapeutics' success is fundamentally dependent on the successful development, completion of clinical trials, and subsequent regulatory approval of its pipeline candidates. There is significant uncertainty in the outcome of clinical trials, which can fail at any stage due to lack of efficacy, safety concerns, or other unforeseen issues. Even if clinical trials are successful, there is no guarantee that regulatory authorities, such as the FDA, will approve the company's drug candidates for commercialization.
- Significant Capital Requirements and Need for Future Funding: The development of new drugs is an extremely costly and lengthy process. vTv Therapeutics, being a clinical-stage company with no commercialized products, relies heavily on securing substantial external funding to continue its research and development activities, advance its multiple pipeline programs (including TTP399, HPP737, TTP273, HPP3033, azeliragon, and HPP971), and ultimately fund the potential commercialization of any approved products. The inability to secure sufficient additional funding on acceptable terms could significantly impede its operations and future growth.
- Intellectual Property Risks: The value of vTv Therapeutics' product candidates is substantially dependent on its ability to obtain, maintain, and enforce patent and other intellectual property protection for its various compounds and technologies. There is a risk that the company may not be able to obtain adequate patent protection for its drug candidates, or that existing or future patents may be challenged, invalidated, or circumvented by competitors. Failure to protect its intellectual property could significantly undermine its ability to commercialize its products and maintain a competitive advantage.
AI Analysis | Feedback
The clear emerging threat to vTv Therapeutics is the potential for the widespread adoption of curative or disease-modifying therapies for Type 1 Diabetes (T1D). As a clinical-stage company developing TTP399, an orally administered glucokinase activator for the treatment of T1D, vTv's market potential for this asset could be fundamentally disrupted by advancements in areas such as stem cell-derived islet transplantation or gene therapies that aim to functionally cure or reverse T1D rather than merely manage its symptoms. The increasing progress in these curative approaches represents a paradigm shift that could significantly diminish the need for chronic T1D treatments, analogous to how new technologies or business models have disrupted traditional industries.
AI Analysis | Feedback
Addressable Markets for vTv Therapeutics' Main Products
- TTP399 (Type 1 Diabetes): The global addressable market for Type 1 Diabetes is estimated to be between USD 16.01 billion and USD 37.60 billion in 2024-2025. This market is projected to grow to a range of approximately USD 26.22 billion to USD 79.14 billion by 2032-2035.
-
HPP737 (Inflammatory diseases and psoriasis):
- Psoriasis: The global psoriasis market size was valued at approximately USD 28.1 billion to USD 31.68 billion in 2024-2025. It is projected to reach between USD 55.8 billion and USD 68.4 billion by 2031-2034.
- Inflammatory Diseases (General): The broader global inflammatory diseases market (excluding biologics specifically) was valued at approximately USD 22.5 billion to USD 22.91 billion in 2025, with projections to reach between USD 34.9 billion and USD 36.78 billion by 2032-2035.
- TTP273 (Cystic Fibrosis Related Diabetes, addressed within the broader Cystic Fibrosis market): The global cystic fibrosis market, which encompasses treatments for the condition, was valued between USD 10.36 billion and USD 13.88 billion in 2023-2025. This market is anticipated to grow significantly, reaching between USD 35.68 billion and USD 74.54 billion by 2032-2035.
-
Azeliragon (Pancreatic and breast cancers, inflammatory lung diseases):
- Pancreatic Cancer: The global pancreatic cancer market was valued between USD 2.65 billion and USD 3.28 billion in 2024-2025. Forecasts indicate growth to between USD 5.76 billion and USD 12.05 billion by 2030-2035.
- Breast Cancer: The global breast cancer therapeutics and drugs market was estimated between USD 26.23 billion and USD 38.41 billion in 2024-2025. Projections show this market expanding to a range of approximately USD 40.11 billion to USD 89.91 billion by 2033-2035.
- Inflammatory Lung Diseases (specifically Interstitial Lung Diseases as a proxy): The market for Interstitial Lung Diseases (ILD) was valued between USD 1.15 billion and USD 1.59 billion globally, or across the top 7 markets (US, EU4, UK, and Japan), in 2024. It is expected to grow to between USD 1.96 billion and USD 2.75 billion by 2033-2035.
AI Analysis | Feedback
Expected Drivers of Future Revenue Growth for vTv Therapeutics (VTVT)
Over the next 2-3 years, vTv Therapeutics' revenue growth is anticipated to be primarily driven by a combination of milestone payments and potential royalties stemming from its strategic partnerships and the advancement of its key clinical-stage assets. As a clinical-stage biopharmaceutical company, direct product sales are not expected in the immediate future. Here are 3-5 expected drivers of future revenue growth:- Milestone and Royalty Payments from HPP737 Global Licensing Agreement: The expanded worldwide licensing agreement with Newsoara Biopharma Co. Ltd. for the PDE4 inhibitor HPP737 is a significant near-term revenue driver. This agreement, amended in February 2026, resulted in an immediate $20 million upfront payment to vTv. Additionally, the deal includes potential future development milestones of up to approximately $50 million and sales milestones of up to $65 million, along with tiered royalties on net sales. As Newsoara advances HPP737 through its clinical development for inflammatory diseases like psoriasis, these milestone payments are expected to contribute to vTv's revenue.
- Advancement and Potential Commercialization of Cadisegliatin (TTP399) for Type 1 Diabetes: Cadisegliatin, a liver-selective glucokinase activator, is vTv Therapeutics' lead candidate and holds FDA Breakthrough Therapy designation for the treatment of type 1 diabetes (T1D). The company expects to complete enrollment in its Phase 3 CATT1 trial in the third quarter of 2026, with topline data anticipated in the second half of 2026. Positive results could pave the way for regulatory filings and eventual commercialization, potentially through existing partners like G42 Healthcare, which is co-funding trials and holds licensing rights in certain territories outside the U.S. and E.U. Such progress would trigger further milestone payments and, eventually, royalties from product sales.
- Milestone Payments from Cadisegliatin (TTP399) Development in Type 2 Diabetes: In December 2025, vTv Therapeutics, in collaboration with M42's Insights Research Organization & Solutions (IROS), submitted a Phase 2 clinical study protocol for cadisegliatin in type 2 diabetes (T2D) to the United Arab Emirates Department of Health. This trial is expected to begin in Q1 2026 and aims to evaluate cadisegliatin as an adjunctive therapy to insulin in T2D patients in specific regions. The initiation and progress of this Phase 2 program, along with potential future advancements, are expected to generate milestone payments from the existing partnership with G42 Healthcare.
AI Analysis | Feedback
Share Issuance
- vTv Therapeutics completed an $80 million private placement of Class A shares and warrants to institutional investors in September 2025.
- The company closed a $51 million private placement in February 2024, issuing common stock and pre-funded warrants to healthcare-focused institutional investors, including Samsara BioCapital, LLC and the JDRF T1D Fund.
- In June 2022, G42 Investments AI Holding RSC Ltd invested $25 million, acquiring 10,386,274 shares of Class A Common Stock at $2.407 per share.
Inbound Investments
- vTv Therapeutics received an immediate $20 million upfront payment from Newsoara Biopharma Co. Ltd. in February 2026, as part of an amended global license agreement for the PDE4 inhibitor HPP737. This agreement also includes potential for up to an additional $115 million in future development and sales milestones, plus tiered royalties.
- In September 2025, the company secured $80 million in financing through a private placement with top healthcare investors.
- vTv Therapeutics closed a $51 million private placement with healthcare-focused institutional investors, including Samsara BioCapital, LLC and the JDRF T1D Fund, in February 2024.
Peer Outperformance in Biotechnology
VTVT has outperformed 62% of its 361 Biotechnology peers over 5Y. Biotechnology ranks 9th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Biotechnology constituents that VTVT has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
76%
of 453 industry peers · 32.9% return
3Y
71%
of 401 industry peers · 59.5% return
5Y
62%
of 361 industry peers · -51.9% return
null
Median price return by industry across the Health Care sector, ranked by 5Y. Biotechnology is VTVT's own industry. Use this to see which corners of the sector have carried the returns.
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 6 | 14.6% | 45.3% | 93.9% | CAH 427% · MCK 373% · COR 181% |
| Health Care Facilities | 24 | 0.4% | 5.6% | 9.6% | THC 307% · NHC 280% · ENSG 140% |
| Health Care Services | 20 | 20.8% | 36.1% | 8.3% | HIMS 296% · RDNT 144% · DGX 75% |
| Managed Health Care | 8 | 27.5% | -7.2% | 3.4% | OSCR 101% · HQY 40% · ELV 13% |
| Health Care Equipment | 50 | -8.4% | -2.5% | -18.3% | POCI 11150% · UFPT 370% · GKOS 252% |
| Pharmaceuticals | 62 | -7.8% | -6.9% | -32.6% | INDV 1105% · ETON 1034% · LQDA 842% |
| Health Care Supplies | 11 | 12.8% | -11.8% | -42.2% | LNTH 301% · HAE 51% · MMSI 17% |
| Life Sciences Tools & Services | 109 | -10.6% | -13.2% | -64.8% | SNWV 2022% · NTRA 244% · MEDP 212% |
| Biotechnology ← | 362 | -18.0% | -26.3% | -79.4% | CELZ 1186% · DNTH 1091% · ELVN 1027% |
| Health Care Technology | 20 | -31.9% | -55.1% | -80.7% | SPOK 79% · HSTM 11% · VEEV -2% |
Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| vTv Therapeutics Earnings Notes | 12/16/2025 | |
| Is vTv Therapeutics Stock Built to Withstand a Pullback? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 5.44 |
| Mkt Cap | 0.1 |
| Rev LTM | 18 |
| Op Inc LTM | -9 |
| FCF LTM | -9 |
| FCF 3Y Avg | -5 |
| CFO LTM | -9 |
| CFO 3Y Avg | -5 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 10.2% |
| Rev Chg 3Y Avg | 9.8% |
| Rev Chg Q | 10.6% |
| QoQ Delta Rev Chg LTM | 2.1% |
| Op Inc Chg LTM | -53.0% |
| Op Inc Chg 3Y Avg | 22.9% |
| Op Mgn LTM | -1.5% |
| Op Mgn 3Y Avg | -0.7% |
| QoQ Delta Op Mgn LTM | -0.2% |
| CFO/Rev LTM | -9.2% |
| CFO/Rev 3Y Avg | 0.3% |
| FCF/Rev LTM | -10.1% |
| FCF/Rev 3Y Avg | -0.4% |
Price Behavior
Price Behavior
| Market Price | $30.03 | |
| Market Cap ($ Bil) | 0.4 | |
| First Trading Date | 07/30/2015 | |
| Distance from 52W High | -29.7% | |
| 50 Days | 200 Days | |
| DMA Price | $30.35 | $33.62 |
| DMA Trend | indeterminate | down |
| Distance from DMA | -1.1% | -10.7% |
| 3M | 1YR | |
| Volatility | 39.0% | 72.2% |
| Downside Capture | 87.11 | 85.77 |
| Upside Capture | 3.83 | 103.13 |
| Correlation (SPY) | 6.1% | 19.1% |
VTVT Betas & Captures as of 9/30/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.86 | 0.11 | 0.28 | 1.00 | 1.08 | 0.95 |
| Up Beta | -2.28 | -0.49 | 0.16 | 1.72 | 1.32 | 1.33 |
| Down Beta | 2.28 | 0.67 | -0.72 | 0.74 | 1.21 | 1.20 |
| Up Capture | 85% | 6% | 5% | 31% | 106% | 32% |
| Bmk +ve Days | 6 | 16 | 27 | 66 | 132 | 424 |
| Stock +ve Days | 9 | 20 | 31 | 59 | 129 | 355 |
| Down Capture | 147% | 58% | 126% | 131% | 88% | 81% |
| Bmk -ve Days | 16 | 26 | 37 | 60 | 120 | 328 |
| Stock -ve Days | 12 | 21 | 32 | 66 | 121 | 375 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with VTVT | |
|---|---|---|---|---|
| VTVT | 20.8% | 72.4% | 0.56 | - |
| Sector ETF (XLV) | 16.9% | 15.7% | 0.79 | 9.0% |
| Equity (SPY) | 17.5% | 13.0% | 0.96 | 18.9% |
| Gold (GLD) | 6.9% | 29.6% | 0.23 | 4.1% |
| Commodities (DBC) | 46.1% | 20.8% | 1.71 | -11.5% |
| Real Estate (VNQ) | 2.1% | 13.7% | -0.10 | -2.1% |
| Bitcoin (BTCUSD) | -29.8% | 44.3% | -0.67 | 18.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with VTVT | |
|---|---|---|---|---|
| VTVT | -13.5% | 96.7% | 0.24 | - |
| Sector ETF (XLV) | 7.1% | 15.2% | 0.28 | 9.6% |
| Equity (SPY) | 13.9% | 17.1% | 0.62 | 15.7% |
| Gold (GLD) | 18.7% | 18.9% | 0.80 | 3.7% |
| Commodities (DBC) | 10.3% | 19.5% | 0.40 | 1.0% |
| Real Estate (VNQ) | 1.2% | 18.8% | -0.04 | 11.6% |
| Bitcoin (BTCUSD) | 16.0% | 52.2% | 0.47 | 14.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with VTVT | |
|---|---|---|---|---|
| VTVT | -19.8% | 119.9% | 0.30 | - |
| Sector ETF (XLV) | 10.6% | 16.7% | 0.51 | 8.9% |
| Equity (SPY) | 15.6% | 17.9% | 0.74 | 11.6% |
| Gold (GLD) | 11.6% | 16.4% | 0.58 | 4.1% |
| Commodities (DBC) | 8.3% | 18.1% | 0.37 | 3.1% |
| Real Estate (VNQ) | 4.2% | 20.7% | 0.16 | 8.8% |
| Bitcoin (BTCUSD) | 64.1% | 66.2% | 1.04 | 9.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 10/6/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/6/2026 | 2.2% | -10.9% | -3.6% |
| 5/13/2026 | 21.4% | 15.6% | 3.5% |
| 3/10/2026 | 0.2% | 4.8% | 6.5% |
| 11/6/2025 | 2.2% | 22.8% | 26.7% |
| 8/12/2025 | -3.2% | 7.1% | 38.4% |
| 5/15/2025 | -6.2% | -13.2% | -29.1% |
| 3/20/2025 | -5.5% | -2.6% | 11.7% |
| 11/12/2024 | 7.1% | 18.1% | 12.9% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 9 | 11 | 12 |
| # Negative | 13 | 11 | 10 |
| Median Positive | 2.2% | 4.8% | 12.6% |
| Median Negative | -3.2% | -5.4% | -16.8% |
| Max Positive | 21.4% | 30.9% | 66.0% |
| Max Negative | -11.7% | -16.9% | -32.7% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/6/2026 | 2.2% | -10.9% | -3.6% |
| 5/13/2026 | 21.4% | 15.6% | 3.5% |
| 3/10/2026 | 0.2% | 4.8% | 6.5% |
| 11/6/2025 | 2.2% | 22.8% | 26.7% |
| 8/12/2025 | -3.2% | 7.1% | 38.4% |
| 5/15/2025 | -6.2% | -13.2% | -29.1% |
| 3/20/2025 | -5.5% | -2.6% | 11.7% |
| 11/12/2024 | 7.1% | 18.1% | 12.9% |
| 8/8/2024 | -1.8% | 0.0% | 12.3% |
| 5/9/2024 | -3.1% | 3.9% | -32.6% |
| 3/13/2024 | 0.4% | 30.9% | 59.1% |
| 8/11/2023 | 2.6% | -6.9% | -32.7% |
| 5/11/2023 | -5.6% | 4.5% | -12.2% |
| 3/6/2023 | -4.8% | -16.9% | -16.7% |
| 11/10/2022 | -2.4% | -5.4% | -13.4% |
| 8/15/2022 | -11.7% | -16.1% | -16.8% |
| 5/12/2022 | -4.7% | -0.1% | 66.0% |
| 11/9/2021 | 0.0% | 3.3% | -20.7% |
| 8/4/2021 | -2.6% | -3.6% | -3.6% |
| 5/5/2021 | -2.1% | -4.9% | 2.9% |
| 2/24/2021 | 0.4% | -3.6% | 7.1% |
| 11/5/2020 | -1.8% | 0.6% | 21.8% |
| SUMMARY STATS | |||
| # Positive | 9 | 11 | 12 |
| # Negative | 13 | 11 | 10 |
| Median Positive | 2.2% | 4.8% | 12.6% |
| Median Negative | -3.2% | -5.4% | -16.8% |
| Max Positive | 21.4% | 30.9% | 66.0% |
| Max Negative | -11.7% | -16.9% | -32.7% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/06/2026 | 10-Q |
| 03/31/2026 | 05/13/2026 | 10-Q |
| 12/31/2025 | 03/10/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/12/2025 | 10-Q |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 03/20/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 03/13/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/11/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/06/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/06/2026 | 10-Q |
| 03/31/2026 | 05/13/2026 | 10-Q |
| 12/31/2025 | 03/10/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/12/2025 | 10-Q |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 03/20/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 03/13/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/11/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/06/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| 06/30/2022 | 08/15/2022 | 10-Q |
| 03/31/2022 | 05/12/2022 | 10-Q |
| 12/31/2021 | 03/29/2022 | 10-K |
| 09/30/2021 | 11/09/2021 | 10-Q |
| 06/30/2021 | 08/04/2021 | 10-Q |
| 03/31/2021 | 05/05/2021 | 10-Q |
| 12/31/2020 | 02/24/2021 | 10-K |
| 09/30/2020 | 11/05/2020 | 10-Q |
| 06/30/2020 | 08/03/2020 | 10-Q |
| 03/31/2020 | 05/07/2020 | 10-Q |
| 12/31/2019 | 02/21/2020 | 10-K |
| 09/30/2019 | 10/30/2019 | 10-Q |
Investor Activity (13F)
Updated Oct 7, 202613F holdings as of Mar 31, 2026 (Q1 2026)
Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
| Active Manager |
|---|
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 10/6/2026